$PSTX
Poseida Therapeutics, Inc.

2023 Q1 Form 10-K Financial Statement

#000095017023007030 Filed on March 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $10.34M $10.05M $130.5M
YoY Change 620.77% -67.82% 317.73%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $11.81M $9.368M $37.54M
YoY Change 23.69% -2.51% 4.52%
% of Gross Profit
Research & Development $38.05M $33.90M $152.9M
YoY Change -6.62% -13.3% 11.82%
% of Gross Profit
Depreciation & Amortization $1.324M $1.355M $5.172M
YoY Change 9.69% 14.54% 13.62%
% of Gross Profit
Operating Expenses $49.86M $43.27M $190.4M
YoY Change -0.87% -11.17% 10.3%
Operating Profit -$39.52M -$59.95M
YoY Change -30.63% -57.61%
Interest Expense $2.028M -$1.975M $6.370M
YoY Change -288.3% 135.12% -289.7%
% of Operating Profit
Other Income/Expense, Net $2.697M $2.170M $2.858M
YoY Change -14294.74% 656.1% 868.81%
Pretax Income -$38.85M -$33.03M -$63.46M
YoY Change -33.09% -2348.2% -49.22%
Income Tax $292.0K $544.0K
% Of Pretax Income
Net Earnings -$38.80M -$33.32M -$64.00M
YoY Change -33.17% -2368.07% -48.8%
Net Earnings / Revenue -375.13% -331.49% -49.05%
Basic Earnings Per Share -$0.45 -$0.89
Diluted Earnings Per Share -$0.45 -$0.39 -$0.89
COMMON SHARES
Basic Shares Outstanding 86.53M 85.95M 71.95M
Diluted Shares Outstanding 86.27M 71.95M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $247.2M $282.5M $282.5M
YoY Change 34.72% 36.92% 36.92%
Cash & Equivalents $40.14M $81.38M $81.38M
Short-Term Investments $207.1M $201.1M $201.1M
Other Short-Term Assets $5.058M $6.982M $6.982M
YoY Change -27.96% -7.5% -7.5%
Inventory
Prepaid Expenses
Receivables $8.437M $9.088M $9.088M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $260.7M $298.6M $298.6M
YoY Change 36.84% 39.6% 39.6%
LONG-TERM ASSETS
Property, Plant & Equipment $22.11M $21.59M $46.67M
YoY Change 0.06% -2.1% -3.23%
Goodwill $4.228M $4.228M
YoY Change 0.0% 0.0%
Intangibles $1.320M $1.320M
YoY Change 0.0% 0.0%
Long-Term Investments
YoY Change
Other Assets $1.055M $1.055M $1.055M
YoY Change 0.86% -36.48% -36.48%
Total Long-Term Assets $52.93M $53.27M $53.27M
YoY Change -8.18% -3.9% -3.9%
TOTAL ASSETS
Total Short-Term Assets $260.7M $298.6M $298.6M
Total Long-Term Assets $52.93M $53.27M $53.27M
Total Assets $313.6M $351.8M $351.8M
YoY Change 26.38% 30.64% 30.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.200M $2.228M $2.228M
YoY Change -10.84% -75.14% -75.14%
Accrued Expenses $20.42M $28.05M $28.05M
YoY Change -37.96% 2.4% 2.4%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $48.69M $53.89M $53.89M
YoY Change 10.87% 24.35% 24.35%
LONG-TERM LIABILITIES
Long-Term Debt $58.32M $58.25M $58.25M
YoY Change 0.61% 98.42% 98.42%
Other Long-Term Liabilities $2.245M $2.091M $52.05M
YoY Change -94.72% 31.51% 29.0%
Total Long-Term Liabilities $60.57M $60.34M $110.3M
YoY Change -39.72% 94.98% 58.23%
TOTAL LIABILITIES
Total Short-Term Liabilities $48.69M $53.89M $53.89M
Total Long-Term Liabilities $60.57M $60.34M $110.3M
Total Liabilities $156.1M $164.2M $164.2M
YoY Change 8.03% 45.22% 45.22%
SHAREHOLDERS EQUITY
Retained Earnings -$509.7M -$470.9M
YoY Change 9.64% 15.74%
Common Stock $667.3M $658.6M
YoY Change 16.97%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $157.6M $187.6M $187.6M
YoY Change
Total Liabilities & Shareholders Equity $313.6M $351.8M $351.8M
YoY Change 26.38% 30.64% 30.64%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$38.80M -$33.32M -$64.00M
YoY Change -33.17% -2368.07% -48.8%
Depreciation, Depletion And Amortization $1.324M $1.355M $5.172M
YoY Change 9.69% 14.54% 13.62%
Cash From Operating Activities -$38.00M $2.403M -$26.80M
YoY Change -25.93% -71.64% -73.85%
INVESTING ACTIVITIES
Capital Expenditures $784.0K $260.0K $3.924M
YoY Change 5.52% -222.07% 48.97%
Acquisitions
YoY Change
Other Investing Activities -$3.631M -$85.63M -$199.4M
YoY Change -475822.22% -188.62%
Cash From Investing Activities -$4.415M -$85.89M -$203.3M
YoY Change 494.21% 43946.15% -191.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $75.30M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.186M 58.00K 105.2M
YoY Change -95.94% -75.42% 4076.29%
NET CHANGE
Cash From Operating Activities -38.00M 2.403M -26.80M
Cash From Investing Activities -4.415M -85.89M -203.3M
Cash From Financing Activities 1.186M 58.00K 105.2M
Net Change In Cash -41.23M -83.43M -124.9M
YoY Change 80.57% -1079.9% -202.12%
FREE CASH FLOW
Cash From Operating Activities -$38.00M $2.403M -$26.80M
Capital Expenditures $784.0K $260.0K $3.924M
Free Cash Flow -$38.78M $2.143M -$30.72M
YoY Change -25.48% -75.33% -70.78%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001661460
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 us-gaap Defined Contribution Plan Tax Status Extensible List
DefinedContributionPlanTaxStatusExtensibleList
http://fasb.org/us-gaap/2022#QualifiedPlanMember
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Entity Registrant Name
EntityRegistrantName
Poseida Therapeutics, Inc.
CY2021 us-gaap Defined Contribution Plan Tax Status Extensible List
DefinedContributionPlanTaxStatusExtensibleList
http://fasb.org/us-gaap/2022#QualifiedPlanMember
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-39376
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-2846548
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
9390 Towne Centre Drive
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
CY2022 dei City Area Code
CityAreaCode
858
CY2022 dei Local Phone Number
LocalPhoneNumber
779-3100
CY2022 dei Security12b Title
Security12bTitle
Common stock, $0.0001 par value per share
CY2022 dei Trading Symbol
TradingSymbol
PSTX
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
99900000
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
86527203
CY2022 dei Auditor Firm
AuditorFirmId
238
CY2022 dei Auditor Name
AuditorName
PricewaterhouseCoopers LLP
CY2022 dei Auditor Location
AuditorLocation
Irvine, California
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
81378000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
206325000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
201115000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9088000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6982000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7548000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
298563000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
213873000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21586000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22050000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
25085000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
26177000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1320000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1320000
CY2022Q4 us-gaap Goodwill
Goodwill
4228000
CY2021Q4 us-gaap Goodwill
Goodwill
4228000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1055000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1661000
CY2022Q4 us-gaap Assets
Assets
351837000
CY2021Q4 us-gaap Assets
Assets
269309000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2228000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8961000
CY2022Q4 pstx Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
26068000
CY2021Q4 pstx Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
23540000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5866000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6337000
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
19723000
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
4497000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
53885000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
43335000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
58250000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
29357000
CY2022Q4 pstx Deferred Cirm Grant Liability Noncurrent
DeferredCIRMGrantLiabilityNoncurrent
3992000
CY2021Q4 pstx Deferred Cirm Grant Liability Noncurrent
DeferredCIRMGrantLiabilityNoncurrent
3992000
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
21333000
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
9265000
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
55000
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
55000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
24636000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
25504000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2091000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1590000
CY2022Q4 us-gaap Liabilities
Liabilities
164242000
CY2021Q4 us-gaap Liabilities
Liabilities
113098000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
85964161
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
85964161
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
62523596
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
62523596
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
9000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
658596000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
563064000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-149000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-470861000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-406859000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
187595000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
156211000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
351837000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
269309000
CY2022 us-gaap Revenues
Revenues
130492000
CY2021 us-gaap Revenues
Revenues
31238000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
152899000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
136734000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
37539000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
35915000
CY2022 us-gaap Operating Expenses
OperatingExpenses
190438000
CY2021 us-gaap Operating Expenses
OperatingExpenses
172649000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-59946000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-141411000
CY2022 us-gaap Interest Expense
InterestExpense
6370000
CY2021 us-gaap Interest Expense
InterestExpense
3358000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2858000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
19795000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-63458000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-124974000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
544000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-64002000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-124974000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-149000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-5000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-64151000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-124979000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.89
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.89
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.01
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.01
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71953703
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
71953703
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62235940
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62235940
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
261968000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2518000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16704000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-5000
us-gaap Net Income Loss
NetIncomeLoss
-124974000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
156211000
CY2022 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1310000
CY2022 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
5223000
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
75299000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18926000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-149000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-64002000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
187595000
CY2022 us-gaap Profit Loss
ProfitLoss
-64002000
CY2021 us-gaap Profit Loss
ProfitLoss
-124974000
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
5172000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
4552000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
18926000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
16704000
CY2021 pstx Write Off Of Deferred Grant Liability
WriteOffOfDeferredGrantLiability
-19763000
CY2022 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-844000
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-639000
CY2022 pstx Amortization Accretion On Investment Securities Net
AmortizationAccretionOnInvestmentSecuritiesNet
-1775000
CY2021 pstx Amortization Accretion On Investment Securities Net
AmortizationAccretionOnInvestmentSecuritiesNet
133000
CY2022 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-348000
CY2021 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
2000
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
9088000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-499000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2656000
CY2022 pstx Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
4605000
CY2021 pstx Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
3580000
CY2022 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-605000
CY2021 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-1957000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-6748000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
7842000
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1399000
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1204000
CY2022 pstx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-4852000
CY2021 pstx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-3113000
CY2022 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
27295000
CY2021 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
13762000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26772000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-102543000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3924000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2634000
CY2022 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
12000
CY2021 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
18000
CY2022 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
294422000
CY2022 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
95000000
CY2021 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
225000000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-203334000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
222384000
CY2022 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1310000
CY2021 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2518000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
75299000
CY2022 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
30000000
CY2022 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
1450000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
105159000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2518000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-124947000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
122359000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
206325000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
83966000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
81378000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
206325000
CY2022 pstx Purchases Of Property And Equipment Included In Accounts Payable And Accrued Liabilities
PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities
1144000
CY2021 pstx Purchases Of Property And Equipment Included In Accounts Payable And Accrued Liabilities
PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities
647000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4425000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4771000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
5138000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
2719000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-64000000.0
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-125000000.0
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26800000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-102500000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-470900000
CY2022Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
282500000
CY2022 pstx Contract With Customer Liability Amounts Received Invoiced
ContractWithCustomerLiabilityAmountsReceivedInvoiced
157786000
CY2022 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-130492000
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company evaluates its estimates, which include, but are not limited to, estimates related to revenue, accrued expenses, stock-based compensation expense, deferred tax valuation allowances. The Company bases its estimates on historical experience and other market-specific or relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</span></p>
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
41056000
CY2022 us-gaap Variable Lease Payment
VariableLeasePayment
0
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and short-term investments. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. Deposits held at these institutions may exceed the amount of insurance provided on such deposits.</span></p>
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
1800000
CY2022Q4 pstx Debt Instrument Final Payment Fee Accrued
DebtInstrumentFinalPaymentFeeAccrued
2100000
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2021 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022 pstx Number Of Revenue Performance Obligation
NumberOfRevenuePerformanceObligation
1
CY2022 pstx Number Of Reportable Segment
NumberOfReportableSegment
1
CY2022 pstx Number Of Customer
NumberOfCustomer
2
CY2022 us-gaap Revenue Performance Obligation Description Of Payment Terms
RevenuePerformanceObligationDescriptionOfPaymentTerms
Payment terms on invoiced amounts are typically 30 - 60 days.
CY2022 pstx Costs Incurred To Obtain Contracts
CostsIncurredToObtainContracts
0
CY2022 us-gaap Revenue Performance Obligation Description Of Payment Terms
RevenuePerformanceObligationDescriptionOfPaymentTerms
Payment terms on invoiced amounts are typically 30 - 60 days.
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2022 pstx Dividend Yield Assumption Rate
DividendYieldAssumptionRate
0
CY2022 us-gaap Dividends Share Based Compensation
DividendsShareBasedCompensation
0
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
0
CY2022Q4 pstx Prepaid Contract Research Services
PrepaidContractResearchServices
2465000
CY2021Q4 pstx Prepaid Contract Research Services
PrepaidContractResearchServices
2739000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1507000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
2355000
CY2022Q4 us-gaap Prepaid Rent
PrepaidRent
492000
CY2021Q4 us-gaap Prepaid Rent
PrepaidRent
354000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
2518000
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
2100000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6982000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7548000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
35062000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
31187000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
13476000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9137000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21586000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22050000
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
5200000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
4600000
CY2021 pstx Contract With Customer Liability Amounts Received Invoiced
ContractWithCustomerLiabilityAmountsReceivedInvoiced
45000000
CY2021 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-31238000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
13762000
CY2022Q4 us-gaap Goodwill
Goodwill
4228000
CY2021Q4 us-gaap Goodwill
Goodwill
4228000
CY2022Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1320000
CY2021Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1320000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1320000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1320000
CY2021 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2021 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
CY2022 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
CY2022Q4 pstx Accrued Contract Research Services Current
AccruedContractResearchServicesCurrent
10908000
CY2021Q4 pstx Accrued Contract Research Services Current
AccruedContractResearchServicesCurrent
12292000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11271000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8760000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3889000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2488000
CY2022Q4 pstx Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
26068000
CY2021Q4 pstx Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
23540000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
264319000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
13000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
162000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
264170000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
176102000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
176102000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
0
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
0
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
300000
CY2022Q4 pstx Common Stock Dividends Declared
CommonStockDividendsDeclared
0
CY2022 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock is entitled to one vote.
CY2022Q4 pstx Common Stock Dividends Declared
CommonStockDividendsDeclared
0
CY2022Q4 pstx Stock Options Issued And Outstanding
StockOptionsIssuedAndOutstanding
11861881
CY2022Q4 pstx Restricted Stock Units Issued And Outstanding
RestrictedStockUnitsIssuedAndOutstanding
2614402
CY2022Q4 pstx Authorized For Future Options And Award Grants
AuthorizedForFutureOptionsAndAwardGrants
4188473
CY2022Q4 pstx Authorized For Future Issuance Under Employee Stock Purchase Plan
AuthorizedForFutureIssuanceUnderEmployeeStockPurchasePlan
1450822
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
20115578
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9899707
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.57
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M25D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4101635
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.68
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
111911
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.72
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
2027550
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
9.52
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11861881
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.61
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M15D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
7730000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
11861881
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
7.61
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y2M15D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
7730000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5006884
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.88
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y6M25D
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2400000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.64
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.12
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3400000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
200000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2000000.0
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
22100000
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
16700000
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
30800000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0216
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0078
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8494
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8251
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M19D
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M23D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
5107000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
5260000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
10999000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
40024000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
9522000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
30502000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5866000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
24636000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18926000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16704000
CY2018Q4 pstx Lessee Operating Lease Commencement Date
LesseeOperatingLeaseCommencementDate
2019-04-01
CY2018Q4 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2029-12-31
CY2019Q4 pstx Lessee Operating Lease Commencement Date
LesseeOperatingLeaseCommencementDate
2020-07-29
CY2019Q4 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2029-12-31
CY2022Q4 us-gaap Security Deposit
SecurityDeposit
300000
CY2021Q4 us-gaap Security Deposit
SecurityDeposit
300000
CY2019Q3 pstx Lessee Operating Lease Commencement Date
LesseeOperatingLeaseCommencementDate
2020-06-26
CY2019Q3 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2029-12-31
CY2022Q4 pstx One Time Cash Security Deposit
OneTimeCashSecurityDeposit
100000
CY2021Q4 pstx One Time Cash Security Deposit
OneTimeCashSecurityDeposit
100000
CY2022Q4 us-gaap Area Of Land
AreaOfLand
110000
CY2022 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
The lease agreements include two options to extend the term for a period of 5 years each.
CY2022 pstx Lessee Operating Lease Number Of Options To Extend Term
LesseeOperatingLeaseNumberOfOptionsToExtendTerm
2
CY2022Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
7000000.0
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
6300000
CY2022 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
600000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
7900000
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y6M
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0892
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
6096000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
6188000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
6374000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-63458000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-124974000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-63458000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-124974000
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
456000
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
88000
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
544000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
544000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
500000
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
13326000
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
26245000
CY2022 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
9026000
CY2021 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
22448000
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
2842000
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
7575000
CY2022 pstx Effective Income Tax Rate Reconciliation Unrecognized Tax Benefits
EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefits
2209000
CY2021 pstx Effective Income Tax Rate Reconciliation Unrecognized Tax Benefits
EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefits
3431000
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
3106000
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
2308000
CY2022 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
171000
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-139000
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
20252000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
50668000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
544000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
89300000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
98815000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
38674000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
33524000
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
23370000
CY2022Q4 pstx Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
8468000
CY2021Q4 pstx Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
8885000
CY2022Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
2584000
CY2021Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
2280000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
2910000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
2233000
CY2022Q4 pstx Deferred Tax Assets Amortization
DeferredTaxAssetsAmortization
1252000
CY2021Q4 pstx Deferred Tax Assets Amortization
DeferredTaxAssetsAmortization
1406000
CY2022Q4 pstx Deferred Tax Assets Grant Income
DeferredTaxAssetsGrantIncome
1108000
CY2021Q4 pstx Deferred Tax Assets Grant Income
DeferredTaxAssetsGrantIncome
1114000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
3612000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2430000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
171278000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
150687000
CY2022Q4 pstx Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
6965000
CY2021Q4 pstx Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
7305000
CY2022Q4 pstx Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
1948000
CY2021Q4 pstx Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
1308000
CY2022Q4 pstx Deferred Tax Liabilities Acquired Indefinite Lived Intangibles
DeferredTaxLiabilitiesAcquiredIndefiniteLivedIntangibles
366000
CY2021Q4 pstx Deferred Tax Liabilities Acquired Indefinite Lived Intangibles
DeferredTaxLiabilitiesAcquiredIndefiniteLivedIntangibles
368000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
9279000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
8981000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
162054000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
141761000
CY2022Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
55000
CY2021Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
55000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
162100000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
141800000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
11800000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
9494000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
5457000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
2403000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
4105000
CY2022 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
92000
CY2021 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
68000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
11805000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
9494000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
11800000
CY2022Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2022Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2022 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1500000
CY2021 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
900000
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14642690
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10026139

Files In Submission

Name View Source Status
pstx-20221231_pre.xml Edgar Link unprocessable
pstx-20221231_def.xml Edgar Link unprocessable
0000950170-23-007030-index-headers.html Edgar Link pending
0000950170-23-007030-index.html Edgar Link pending
0000950170-23-007030.txt Edgar Link pending
0000950170-23-007030-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img24255708_0.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
pstx-20221231_cal.xml Edgar Link unprocessable
img25179229_0.jpg Edgar Link pending
img92633475_0.jpg Edgar Link pending
img92633475_1.jpg Edgar Link pending
img92633475_10.jpg Edgar Link pending
img92633475_11.jpg Edgar Link pending
img92633475_12.jpg Edgar Link pending
img92633475_13.jpg Edgar Link pending
img92633475_14.jpg Edgar Link pending
img92633475_15.jpg Edgar Link pending
img92633475_16.jpg Edgar Link pending
img92633475_17.jpg Edgar Link pending
img92633475_18.jpg Edgar Link pending
img92633475_19.jpg Edgar Link pending
img92633475_2.jpg Edgar Link pending
img92633475_20.jpg Edgar Link pending
img92633475_21.jpg Edgar Link pending
img92633475_3.jpg Edgar Link pending
img92633475_4.jpg Edgar Link pending
img92633475_5.jpg Edgar Link pending
img92633475_6.jpg Edgar Link pending
img92633475_7.jpg Edgar Link pending
img92633475_8.jpg Edgar Link pending
img92633475_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
pstx-20221231.htm Edgar Link pending
pstx-20221231.xsd Edgar Link pending
pstx-ex10_13.htm Edgar Link pending
pstx-ex10_14.htm Edgar Link pending
pstx-ex10_7.htm Edgar Link pending
pstx-ex10_8.htm Edgar Link pending
pstx-ex10_9.htm Edgar Link pending
pstx-ex21_1.htm Edgar Link pending
pstx-ex23_1.htm Edgar Link pending
pstx-ex31_1.htm Edgar Link pending
pstx-ex31_2.htm Edgar Link pending
pstx-ex32_1.htm Edgar Link pending
pstx-ex32_2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
pstx-20221231_lab.xml Edgar Link unprocessable
pstx-20221231_htm.xml Edgar Link completed
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending